Results 261 to 270 of about 1,191,068 (306)
Some of the next articles are maybe not open access.
Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis
Frontiers of Medicine in China, 2010This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen (CA) 19-9 levels in the survival of patients with cholangiocarcinoma. Articles published up to June 1(st), 2010 that evaluated preoperative CA19-9 levels and the prognosis of cholangiocarcinoma were collected for meta-analysis.
Shang-Long, Liu +6 more
openaire +2 more sources
Rheumatoid factor interference in the determination of carbohydrate antigen 19-9 (CA 19-9)
Clinical Chemistry and Laboratory Medicine (CCLM), 2006AbstractClin Chem Lab Med 2006;44:1137–9.
Mario, Berth +6 more
openaire +2 more sources
1995
This tumour-associated antigen is a high molecular weight mucin epitope expression is defined by a homologous monoclonal antibody system — the CA 19-9 antibody The antigenic epitope represents a sialylated Lewisa blood group pentasaccharide and, as such, is similar to that detected by some other monocloncal antibody systems.
openaire +1 more source
This tumour-associated antigen is a high molecular weight mucin epitope expression is defined by a homologous monoclonal antibody system — the CA 19-9 antibody The antigenic epitope represents a sialylated Lewisa blood group pentasaccharide and, as such, is similar to that detected by some other monocloncal antibody systems.
openaire +1 more source
[Carbohydrate antigen CA 19-9: value in pancreatic pathology].
Gastroenterologie clinique et biologique, 1986In order to determine the diagnostic usefulness of the dosage of carbohydrate antigen (CA 19-9) serum levels in pancreatic diseases, 38 patients with pancreatic lesions proved at laparotomy were studied. Pancreatic lesions were classified into two groups: a) group I: pancreatic adenocarcinoma (17 cases) b) group II: benign pancreatic diseases (21 cases)
J, Venot +5 more
openaire +1 more source
CA 19–9, GICA (Gastrointestinal Cancer Antigen)
1992Following the detection and clinical exploitation of alphafetoprotein (AFP), calcinoembryonic antigen (CEA), and human chorionic genadotropin (HCG) as first and basic tumor markers, the discovery of blood group-related carbohydrate structures on glycoproteins and glycolipids as indicators of malignancy has opened a wide array of scientific and clinical
openaire +1 more source
European Journal of Surgical Oncology (EJSO), 2007
Although many biochemical markers have been examined in pancreatic cancer none are definitive for pre-operative diagnosis. This systematic review examines studies using biochemical markers for the diagnosis of pancreatic cancer in order to appraise their role in contemporary management algorithms.A search of the MEDLINE database was undertaken using ...
K S, Goonetilleke, A K, Siriwardena
openaire +2 more sources
Although many biochemical markers have been examined in pancreatic cancer none are definitive for pre-operative diagnosis. This systematic review examines studies using biochemical markers for the diagnosis of pancreatic cancer in order to appraise their role in contemporary management algorithms.A search of the MEDLINE database was undertaken using ...
K S, Goonetilleke, A K, Siriwardena
openaire +2 more sources
Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma.
The Italian journal of surgical sciences, 1985CA 19-9 and CEA serum levels were determined before and 7 days after surgery in 140 patients with gastrointestinal adenocarcinoma, and in 70 patients with gastrointestinal non neoplastic diseases. CA 19-9 test was shown to be positive in 37.9% of colorectal cancer, in 32.6% of gastric cancer and in 77.8% of pancreatic cancer.
MENNINI, Giuseppe +7 more
openaire +2 more sources
Scandinavian Journal of Gastroenterology, 1989
Serum levels of the new tumor-associated marker CA 72-4 were measured in healthy controls (n = 64) and patients with benign (n = 410) or malignant (n = 199) gastrointestinal diseases. A cut-off limit of 4 U/ml was established. Tumor-indicating sensitivity was compared with that of the conventional markers carcinoembryonic antigen (CEA) and CA 19-9.
G, Heptner, S, Domschke, W, Domschke
openaire +2 more sources
Serum levels of the new tumor-associated marker CA 72-4 were measured in healthy controls (n = 64) and patients with benign (n = 410) or malignant (n = 199) gastrointestinal diseases. A cut-off limit of 4 U/ml was established. Tumor-indicating sensitivity was compared with that of the conventional markers carcinoembryonic antigen (CEA) and CA 19-9.
G, Heptner, S, Domschke, W, Domschke
openaire +2 more sources
Serum CA 19-9 and CA 50 antigens in hemodialysis patients.
Clinical nephrology, 1987Serum concentrations of monoclonal antibody-defined tumor markers CA 19-9 and CA 50 were measured in 64 uncomplicated hemodialysis patients (Group 1) and in 8 hemodialysis patients with cancer (Group 2) in comparison with corresponding CEA determinations.
D, Docci +5 more
openaire +1 more source
Expression of the carcinoma-associated antigens CA 19-9 and CA-50 in inflammatory bowel disease
Diseases of the Colon & Rectum, 1987The expression of gastrointestinal cancer antigen, CA 19-9, and of carcinoma-associated antigen, CA-50, was studied in formalin-fixed and paraffin-embedded tissue from 18 patients with ulcerative colitis, 29 with Crohn's disease in the colon, four with diverticular disease, and eight with sigmoid volvulus.
G, Frykholm +3 more
openaire +2 more sources